Disparities in Neuro-Oncology

1.

CDC. Health Disparities. Healthy Youth. https://www.cdc.gov/healthyyouth/disparities/index.htm

2.

• Magnan S. Social Determinants of Health 101 for Health Care. Natl Acad Med Perspect. Published online 2017:1–9. This perspective from the National Academy of Medicine reviews the social determinants of health and their importance on overall health and healthcare.

3.

Social Determinants of Health. Healthy People - US Department of Health and Human Services. Published 2022. https://health.gov/healthypeople/objectives-and-data/social-determinants-health

4.

Chukwueke UN, Hervey-Jumper S, Porter A. Disparities and inequities among patients with central nervous system tumor. Hematol Oncol Clin North Am. 2022;36(1):e1–8. https://doi.org/10.1016/j.hoc.2021.10.002.CrossRefPubMed

5.

• Porter AB, Chukwueke UN, Mammoser AG, Friday B, Hervey-Jumper S. Delivering equitable care to underserved neuro-oncology populations. Am Soc Clin Oncol Educ Book. 2021;41:38–46. https://doi.org/10.1200/edbk_320803. This review covers different ways to achieve health equity in neuro-oncology. Interventions include increasing diversity in clinical trials, increasing access to telemedicine and ways to optimize community practices, and provider education in bias, stereotyping, and racism.CrossRef

6.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

7.

Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro-Oncol. 2022;24(5):v1–95. https://doi.org/10.1093/neuonc/noac202.CrossRefPubMedPubMedCentral

8.

Plascak JJ, Fisher JL. Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data. PLoS ONE. 2013;8(4):e60910. https://doi.org/10.1371/journal.pone.0060910.CrossRefPubMedPubMedCentral

9.

Poynter JN, Fonstad R, Tolar J, Spector LG, Ross JA. Incidence of intracranial germ cell tumors by race in the United States, 1992–2010. J Neurooncol. 2014;120(2):381–8. https://doi.org/10.1007/s11060-014-1562-7.CrossRefPubMedPubMedCentral

10.

• Jackson HN, Hadley CC, Khan AB, et al. Racial and socioeconomic disparities in patients with meningioma: a retrospective cohort study. Neurosurgery. 2022;90(1):114–23. https://doi.org/10.1227/NEU.0000000000001751. Retrospective analysis that showed that minority patients were more likely to present to the emergency department than to an outpatient clinic. Minority patients also had more advanced clinical symptoms at time of presentation and experienced longer postoperative stays.CrossRefPubMed

11.

Butterfield JT, Golzarian S, Johnson R, et al. Racial disparities in recommendations for surgical resection of primary brain tumours: a registry-based cohort analysis. Lancet Lond Engl. 2022;400(10368):2063–73. https://doi.org/10.1016/S0140-6736(22)00839-X.CrossRef

12.

Bhambhvani HP, Rodrigues AJ, Medress ZA, Hayden GM. Racial and socioeconomic correlates of treatment and survival among patients with meningioma: a population-based study. J Neurooncol. 2020;147(2):495–501. https://doi.org/10.1007/s11060-020-03455-2.CrossRefPubMed

13.

Sherwood PR, Dahman BA, Donovan HS, Mintz A, Given CW, Bradley CJ. Treatment disparities following the diagnosis of an astrocytoma. J Neurooncol. 2011;101(1):67–74. https://doi.org/10.1007/s11060-010-0223-8.CrossRefPubMed

14.

Rivera Perla KM, Tang OY, Durfey SNM, et al. Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the area deprivation index (ADI). J Neurooncol. 2022;158(3):349–57. https://doi.org/10.1007/s11060-022-04020-9.CrossRefPubMed

15.

Burton E, Yusuf M, Gilbert MR, Gaskins J, Woo S. Failure to complete standard radiation therapy in glioblastoma patients: patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients. J Geriatr Oncol. 2020;11(4):680–7. https://doi.org/10.1016/j.jgo.2019.08.014.CrossRefPubMed

16.

Ostrom QT, Krebs HL, Patil N, Cioffi G, Barnholtz-Sloan JS. Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. J Neurooncol. 2021;152(3):603–15. https://doi.org/10.1007/s11060-021-03736-4.CrossRefPubMed

17.

Patel AM, Ali O, Kainthla R, et al. Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting. Neuro-Oncol Pract. 2022;9(3):183–92. https://doi.org/10.1093/nop/npab066.CrossRef

18.

Karsy M, Yoon N, Boettcher L, et al. Surgical treatment of glioblastoma in the elderly: the impact of complications. J Neurooncol. 2018;138(1):123–32. https://doi.org/10.1007/s11060-018-2777-9.CrossRefPubMed

19.

Gulati S, Jakola AS, Nerland US, Weber C, Solheim O. The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg. 2011;76(6):572–9. https://doi.org/10.1016/j.wneu.2011.06.014.CrossRefPubMed

20.

Mukherjee D, Patil CG, Todnem N, et al. Racial disparities in Medicaid patients after brain tumor surgery. J Clin Neurosci Off J Neurosurg Soc Australas. 2013;20(1):57–61. https://doi.org/10.1016/j.jocn.2012.05.014.CrossRef

21.

• Thomas G, Almeida ND, Mast G, et al. Racial disparities affecting postoperative outcomes after brain tumor resection. World Neurosurg. 2021;155:e665–73. https://doi.org/10.1016/j.wneu.2021.08.112. Minority patients have significantly higher rates of postoperative complications, including cardiovascular, pulmonary, and urinary issues. This leads to extended length of stay in comparison to Caucasian patients.CrossRefPubMed

22.

Hodges TR, Labak CM, Mahajan UV, et al. Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database. Neuro-Oncol Adv. 2021;3(1):040. https://doi.org/10.1093/noajnl/vdab040.CrossRef

23.

Curry WT, Barker FG. Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. J Neurooncol. 2009;93(1):25–39. https://doi.org/10.1007/s11060-009-9840-5.CrossRefPubMed

24.

Curry WTJ, Carter BS, Barker FGI. Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988–2004. Neurosurgery. 2010;66(3):427. https://doi.org/10.1227/01.NEU.0000365265.10141.8E.CrossRefPubMed

25.

Rouse C, Gittleman H, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro-Oncol. 2016;18(1):70–7. https://doi.org/10.1093/neuonc/nov249.CrossRefPubMed

26.

Pulido JS, Vierkant RA, Olson JE, Abrey L, Schiff D, O’Neill BP. Racial differences in primary central nervous system lymphoma incidence and survival rates. Neuro-Oncol. 2009;11(3):318–22. https://doi.org/10.1215/15228517-2008-103.CrossRefPubMedPubMedCentral

27.

Vaughn JL, Epperla N. Racial disparities in the survival of patients with primary central nervous system lymphoma in the United States, 2000–2019. Blood. 2022;140(1):13182–3. https://doi.org/10.1182/blood-2022-170762.CrossRef

28.

Estevez-Ordonez D, Abdelrashid M, Coffee E, et al. Racial and socioeconomic disparities in glioblastoma outcomes: a single-center, retrospective cohort study. Cancer. n/a(n/a) https://doi.org/10.1002/cncr.34881

29.

Mirpuri P, Singh M, Rovin RA. The association of preoperative frailty and neighborhood-level disadvantage with outcome in patients with newly diagnosed high grade glioma. World Neurosurg. 2022;166:e949–57. https://doi.org/10.1016/j.wneu.2022.07.138.CrossRefPubMed

30.

Bower A, Hsu FC, Weaver KE, et al. Community economic factors influence outcomes for patients with primary malignant glioma. Neuro-Oncol Pract. 2020;7(4):453–60. https://doi.org/10.1093/nop/npaa010.CrossRef

31.

Liu EK, Yu S, Sulman EP, Kurz SC. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. J Neurooncol. 2020;149(1):55–64. https://doi.org/10.1007/s11060-020-03572-y.CrossRefPubMed

32.

Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54. https://doi.org/10.1007/s11912-011-0203-y.CrossRefPubMed

33.

Hatiboglu MA, Akdur K, Sawaya R. Neurosurgical management of patients with brain metastasis. Neurosurg Rev. 2020;43(2):483–95. https://doi.org/10.1007/s10143-018-1013-6.CrossRefPubMed

34.

Fecci PE, Champion CD, Hoj J, et al. The evolving modern management of brain metastasis. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(22):6570–80. https://doi.org/10.1158/1078-0432.CCR-18-1624.CrossRef

35.

Virnig BA, Baxter NN, Habermann E, Feldman RD, Bradley CJ. A matter of race: early- versus late-stage cancer diagnosis. Health Aff Proj Hope. 2009;28(1):160–8. https://doi.org/10.1377/hlthaff.28.1.160.CrossRef

36.

Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health. 2015;105(12):e60–76. https://doi.org/10.2105/AJPH.2015.302903.CrossRefPubMedPubMedCentral

37.

Chapman EN, Kaatz A, Carnes M. Physicians and implicit bias: how doctors may unwittingly perpetuate health care disparities. J Gen Intern Med. 2013;28(11):1504–10. https://doi.org/10.1007/s11606-013-2441-1.CrossRefPubMedPubMedCentral

38.

Liu D, Schuchard H, Burston B, Yamashita T, Albert S. Interventions to reduce healthcare disparities in cancer screening among minority adults: a systematic review. J Racial Ethn Health Disparities. 2021;8(1):107–26. https://doi.org/10.1007/s40615-020-00763-1.CrossRefPubMed

39.

De la Garza RR, Benton JA, Gelfand Y, et al. Racial disparities in clinical presentation, type of intervention, and in-hospital outcomes of patients with metastatic spine disease: an analysis of 145,809 admissions in the United States. Cancer Epidemiol. 2020;68:101792. https://doi.org/10.1016/j.canep.2020.101792.CrossRef

40.

• Coelho JC, de Souza CG, Chaves F, et al. Non-small-cell lung cancer with CNS metastasis: disparities from a real-world analysis (GBOT-LACOG 0417). JCO Glob Oncol. 2022;8:e2100333. https://doi.org/10.1200/GO.21.00333. Patients at public hospitals were more frequently treated with whole-brain radiation therapy and less frequently with radiosurgery. Median overall survival rates were also significantly higher in private care compared to public care.CrossRefPubMedPubMedCentral

41.

Presley CJ, Soulos PR, Chiang AC, et al. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. J Clin Oncol. 2017;35(15):6563. https://doi.org/10.1200/JCO.2017.35.15_suppl.6563.CrossRef

42.

Sheinson DM, Wong WB, Meyer CS, et al. Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the medicare national coverage determination. JAMA Netw Open. 2021;4(12):1–13. https://doi.org/10.1001/jamanetworkopen.2021.38219.CrossRef

43.

Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and funding of clinical genomic sequencing globally. BMJ Glob Health. 2021;6(2):e004415. https://doi.org/10.1136/bmjgh-2020-004415.CrossRefPubMedPubMedCentral

44.

Hedblom AH, Pruneri G, Quagliata L, et al. Cancer patient management: current use of next-generation sequencing in the EU TOP4. J Cancer Policy. 2023;35:100376. https://doi.org/10.1016/j.jcpo.2022.100376.CrossRefPubMed

45.

• Rodrigues A, Li G, Bhambhvani H, Hayden-Gephart M. Socioeconomic disparities in brain metastasis survival and treatment: a population-based study. World Neurosurg. 2022;158:e636–44. https://doi.org/10.1016/j.wneu.2021.11.036. Large population-based analysis of patients with brain metastases, which showed significant differences in access to treatment. There were also significant differences in survival that correlated with socioeconomic status.CrossRefPubMed

46.

Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB. Radiosurgery for brain metastases: changing practice patterns and disparities in the United States. JNCCN J Natl Compr Cancer Netw. 2017;15(12):1494–502. https://doi.org/10.6004/jnccn.2017.7003.CrossRef

47.

Modh A, Doshi A, Burmeister C, Elshaikh MA, Lee I, Shah M. Disparities in the use of single-fraction stereotactic radiosurgery for the treatment of brain metastases from non-small cell lung cancer. Cureus. 2019;11(2):e4031. https://doi.org/10.7759/cureus.4031.CrossRefPubMedPubMedCentral

48.

Walker GV, Grant SR, Guadagnolo BA, et al. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(28):3118–25. https://doi.org/10.1200/JCO.2014.55.6258.CrossRef

49.

Breathett K, Jones J, Lum HD, et al. Factors Related to physician clinical decision-making for African-American and Hispanic patients: a qualitative meta-synthesis. J Racial Ethn Health Disparities. 2018;5(6):1215–29. https://doi.org/10.1007/s40615-018-0468-z.CrossRefPubMedPubMedCentral

50.

Green AR, Carney DR, Pallin DJ, et al. Implicit bias among physicians and its prediction of thrombolysis decisions for Black and White patients. J Gen Intern Med. 2007;22(9):1231–8. https://doi.org/10.1007/s11606-007-0258-5.CrossRefPubMedPubMedCentral

51.

Roberts TJ, Kesselheim AS, Avorn J. Variation in use of lung cancer targeted therapies across state Medicaid programs, 2020–2021. JAMA Netw Open. 2023;6(1):e2252562. https://doi.org/10.1001/jamanetworkopen.2022.52562.CrossRefPubMedPubMedCentral

52.

Lamba N, Mehanna E, Kearney RB, et al. Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. Neuro-Oncol. 2020;22(9):1339–47. https://doi.org/10.1093/neuonc/noaa054.CrossRefPubMedPubMedCentral

53.

Chan A, Woodruff RK. Comparison of palliative care needs of English- and non-English-speaking patients. J Palliat Care. 1999;15(1):26–30.CrossRefPubMed

54.

Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727–54. https://doi.org/10.1111/j.1475-6773.2006.00629.x.CrossRefPubMedPubMedCentral

55.

• McCray E, Waguia R, de la Garza Ramos R, et al (2022) Racial disparities in inpatient clinical presentation, treatment, and outcomes in brain metastasis. Neuro-Oncol Pract. Published online July 31, npac061 https://doi.org/10.1093/nop/npac061. Minority patients, including Black and Hispanic, were less likely to receive surgical intervention compared to White patients.

56.

• Nuño M, Mukherjee D, Elramsisy A, et al. Racial and gender disparities and the role of primary tumor type on inpatient outcomes following craniotomy for brain metastases. Ann Surg Oncol. 2012;19(8):2657–63. https://doi.org/10.1245/s10434-012-2353-z. Nationwide inpatient Sample dataset from 1998 to 2007, which showed that Black patients had significantly higher morbidity than White patients following craniotomy for brain metastasesCrossRefPubMed

57.

Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381–406. https://doi.org/10.3322/caac.21693.CrossRefPubMed

58.

Nieblas-Bedolla E, Christophers B, Williams JR, Power-Hays A, Jimenez N, Rodriguez A. Racial and ethnic disparities among children with primary central nervous system tumors in the US. J Neurooncol. 2021;152(3):451–66. https://doi.org/10.1007/s11060-021-03738-2.CrossRefPubMed

59.

Austin MT, Hamilton E, Zebda D, et al. Health disparities and impact on outcomes in children with primary central nervous system solid tumors. J Neurosurg Pediatr. 2016;18(5):585–93. https://doi.org/10.3171/2016.5.PEDS15704.CrossRefPubMed

60.

Marin JR, Rodean J, Hall M, et al. Racial and ethnic differences in emergency department diagnostic imaging at US children’s hospitals, 2016–2019. JAMA Netw Open. 2021;4(1):e2033710. https://doi.org/10.1001/jamanetworkopen.2020.33710.CrossRefPubMedPubMedCentral

61.

Weil CR, Lew FH, Williams VM, Burt LM, Ermoian RP, Poppe MM. Patterns of care and utilization disparities in proton radiation therapy for pediatric central nervous system malignancies. Adv Radiat Oncol. 2022;7(6):100868. https://doi.org/10.1016/j.adro.2021.100868.CrossRefPubMedPubMedCentral

62.

Puthenpura V, Canavan ME, Poynter JN, et al. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. Pediatr Blood Cancer. 2021;68(7):e28970. https://doi.org/10.1002/pbc.28970.CrossRefPubMedPubMedCentral

63.

Kehm RD, Spector LG, Poynter JN, Vock DM, Altekruse SF, Osypuk TL. Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival? Cancer. 2018;124(20):4090–7. https://doi.org/10.1002/cncr.31560.CrossRefPubMed

64.

Fineberg R, Zahedi S, Eguchi M, Hart M, Cockburn M, Green AL. Population-based analysis of demographic and socioeconomic disparities in pediatric CNS cancer survival in the United States. Sci Rep. 2020;10(1):4588. https://doi.org/10.1038/s41598-020-61237-2.CrossRefPubMedPubMedCentral

65.

Thuppal S, Propp JM, McCarthy BJ. Average years of potential life lost in those who have died from brain and CNS tumors in the USA. Neuroepidemiology. 2006;27(1):22–7. https://doi.org/10.1159/000093896.CrossRefPubMed

66.

Green AL, Furutani E, Ribeiro KB, Rodriguez GC. Death within 1 month of diagnosis in childhood cancer: an analysis of risk factors and scope of the problem. J Clin Oncol. 2017;35(12):1320–7. https://doi.org/10.1200/JCO.2016.70.3249.CrossRefPubMedPubMedCentral

67.

Merchant TE, Kun LE, Hua CH, et al. Disease control after reduced volume conformal and intensity modulated radiation therapy for childhood craniopharyngioma. Int J Radiat Oncol Biol Phys. 2013;85(4):e187–92. https://doi.org/10.1016/j.ijrobp.2012.10.030.CrossRefPubMed

68.

Mitchell HK, Morris M, Ellis L, Abrahão R, Bonaventure A. Racial/ethnic and socioeconomic survival disparities for children and adolescents with central nervous system tumours in the United States, 2000–2015. Cancer Epidemiol. 2020;64:101644. https://doi.org/10.1016/j.canep.2019.101644.CrossRefPubMed

69.

Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153–65. https://doi.org/10.3322/caac.21443.CrossRefPubMedPubMedCentral

70.

Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2020;29(7):1304–12. https://doi.org/10.1158/1055-9965.EPI-19-1534.CrossRef

71.

Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. The Patient. 2017;10(3):295–309. https://doi.org/10.1007/s40271-016-0204-x.CrossRefPubMed

72.

Timmer M, Vera E, Acquaye A, et al. QOLP-23. Evaluation of financial toxicity (FT) in people with rare central nervous system (CNS) tumors using an innovative web-based study design. Neuro-Oncol. 2021;23(6):vi187–8. https://doi.org/10.1093/neuonc/noab196.743.CrossRefPubMedCentral

73.

• Koenig JL, Sandhu N, Sborov K, et al. Financial toxicity in patients with brain and spine metastases. World Neurosurg. 2021;151:e630–51. https://doi.org/10.1016/j.wneu.2021.04.103. Prospective survey of patients with brain and spine metastases, which showed that having more than 1 emergency department visit and a cancer-related change in employment status were associated with greater likelihood of reporting financial toxicity.CrossRefPubMed

74.

Wharam JF, Zhang F, Wallace J, et al. Vulnerable and less vulnerable women in high-deductible health plans experienced delayed breast cancer care. Health Aff Proj Hope. 2019;38(3):408–15. https://doi.org/10.1377/hlthaff.2018.05026.CrossRef

75.

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330.CrossRefPubMed

76.

Lee A, Shah K, Chino F. Assessment of parking fees at national cancer institute–designated cancer treatment centers. JAMA Oncol. 2020;6(8):1295–7. https://doi.org/10.1001/jamaoncol.2020.1475.CrossRefPubMedPubMedCentral

77.

Dover LL, Dulaney CR, Fiveash JB, et al. Hospital-based end-of-life care and costs for older patients with malignant brain tumors. JAMA Oncol. 2017;3(11):1581–2. https://doi.org/10.1001/jamaoncol.2017.1624.CrossRefPubMedPubMedCentral

78.

Taylor JW, Armstrong T, Kim AH, et al. The lomustine crisis: awareness and impact of the 1500% price hike. Neuro-Oncol. 2019;21(1):1–3. https://doi.org/10.1093/neuonc/noy189.CrossRefPubMed

79.

• Friedman HS, Lee JD. Rogue drug maker first inflates the price of lomustine, then says No to Medicare coverage. The Cancer Letter. Published July 16, 2021. Accessed August 6, 2023. https://cancerletter.com/trials-and-tribulations/20210716_7/. A key chemotherapy drug called lomustine lost Medicare coverage because the drug company and sole manufacturer of the drug, NextSource Pharmaceuticals, decided to withdraw it from the nation’s safety net insurance program.

80.

Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539–40. https://doi.org/10.1001/jamaoncol.2015.0373.CrossRefPubMed

81.

Network NCC. Brain Cancer - Gliomas`. NCCN.

82.

NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research. Accessed August 13, 2023. https://grants.nih.gov/policy/inclusion/women-and-minorities/guidelines.htm

83.

Griggs J, Maingi S, Blinder V, et al. American Society of Clinical Oncology Position Statement: strategies for reducing cancer health disparities among sexual and gender minority populations. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(19):2203–8. https://doi.org/10.1200/JCO.2016.72.0441.CrossRef

84.

Duma N, Vera Aguilera J, Paludo J, et al. Representation of minorities and women in oncology clinical trials: review of the past 14 years. J Oncol Pract. 2017;14(1):e1–10. https://doi.org/10.1200/JOP.2017.025288.CrossRefPubMed

85.

Reihl SJ, Patil N, Morshed RA, et al. A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Neuro-Oncol. 2022;24(8):1341–9. https://doi.org/10.1093/neuonc/noac011.CrossRefPubMedPubMedCentral

86.

Liu Y, Wasilewski A, Mohile NA. Disparities in patient enrollment on glioblastoma clinical trials. CNS Oncol. 2020;9:2. https://doi.org/10.2217/cns-2020-0008.CrossRef

87.

Guerrero S, López-Cortés A, Indacochea A, et al. Analysis of racial/ethnic representation in select basic and applied cancer research studies. Sci Rep. 2018;8(1):1–8. https://doi.org/10.1038/s41598-018-32264-x.CrossRef

88.

Wu M, Miska J, Xiao T, et al. Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism. J Neurooncol. 2019;142(2):375–84. https://doi.org/10.1007/s11060-019-03110-5.CrossRefPubMedPubMedCentral

89.

Dodson S, Spriggs S, Calabrese R, et al. Analysis of NINDS health disparities and health equity research portfolio, 2016–2020: results and a process for transparency, accuracy, and reliability. Neurology. 2023;101(71):S82–91. https://doi.org/10.1212/WNL.0000000000207569.CrossRefPubMed

90.

• Johnston KC, Trevathan E (2023) NINDS health equity strategic planning process overview, high-level recommendations, and guide. Neurology 101:71 1-8 https://doi.org/10.1212/WNL.0000000000207568Summary of a 3-day public workshop with research recommendations by the working group of the National Advisory Neurological Disorders and Stroke Council to the National Institute of Neurological Disorders and Stroke.

91.

Boden-Albala B, Rebello V, Drum E, et al. Use of community-engaged research approaches in clinical interventions for neurologic disorders in the United States: a scoping review and future directions for improving health equity research. Neurology. 2023;101(71):S27–46. https://doi.org/10.1212/WNL.0000000000207563.CrossRefPubMed

92.

Towfighi A, Berger RP, Corley AMS, Glymour MM, Manly JJ, Skolarus LE. Recommendations on social determinants of health in neurologic disease. Neurology. 2023;101(71):S17–26. https://doi.org/10.1212/WNL.0000000000207562.CrossRefPubMed

93.

• Schor NF, Scott P, Litvina EY, et al. Planning and implementing strategically: year 1 of the NINDS 2021–2026 strategic plan. Neurology. 2022;99(24):1099–107. https://doi.org/10.1212/WNL.0000000000201380. At the end of 2020, the National Institute of Neurological Disorders and Stroke created a strategic plan to engage various biomedical and general stakeholders. One year later, this progress report summarizes the latest updates.CrossRefPubMedPubMedCentral

94.

NIMHD Research Framework Details. NIMHD. Accessed August 15, 2023. https://www.nimhd.nih.gov/about/overview/research-framework/research-framework.html

95.

Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870–e191870. https://doi.org/10.1001/jamaoncol.2019.1870.CrossRefPubMedPubMedCentral

96.

Lor M. Systematic review: health promotion and disease prevention among hmong adults in the USA. J Racial Ethn Health Disparities. 2018;5(3):638–61. https://doi.org/10.1007/s40615-017-0410-9.CrossRefPubMed

97.

Shimkhada R, Scheitler AJ, Ponce NA. Capturing racial/ethnic diversity in population-based surveys: data disaggregation of health data for Asian American, Native Hawaiian, and Pacific Islanders (AANHPIs). Popul Res Policy Rev. 2021;40(1):81–102. https://doi.org/10.1007/s11113-020-09634-3.CrossRef

98.

Kauh TJ, Read JG, Scheitler AJ. The critical role of racial/ethnic data disaggregation for health equity. Popul Res Policy Rev. 2021;40(1):1–7. https://doi.org/10.1007/s11113-020-09631-6.CrossRefPubMedPubMedCentral

99.

Patel VR, Gupta A, Blaes AH, Winkfield KM, Haynes AB, Hussaini SMQ. Prevalence of delayed or forgone care due to patient-clinician identity discordance among US cancer survivors. JAMA Oncol. 2023;9(5):719–22. https://doi.org/10.1001/jamaoncol.2023.0242.CrossRefPubMed

100.

Gomez LE, Bernet P. Diversity improves performance and outcomes. J Natl Med Assoc. 2019;111(4):383–92. https://doi.org/10.1016/j.jnma.2019.01.006.CrossRefPubMed

101.

Jackson CS, Nadine GJ. Addressing health and health-care disparities: the role of a diverse workforce and the social determinants of health. Public Health Rep. 2014;129(2):57–61. https://doi.org/10.1177/00333549141291s211.CrossRefPubMedPubMedCentral

102.

Snyder JE, Upton RD, Hassett TC, Lee H, Nouri Z, Dill M. Black representation in the primary care physician workforce and its association with population life expectancy and mortality rates in the US. JAMA Netw Open. 2023;6(4):e236687. https://doi.org/10.1001/jamanetworkopen.2023.6687.CrossRefPubMedPubMedCentral

103.

Thompson HS, Manning M, Mitchell J, et al. Factors associated with racial/ethnic group-based medical mistrust and perspectives on COVID-19 vaccine trial participation and vaccine uptake in the US. JAMA Netw Open. 2021;4(5):1–10. https://doi.org/10.1001/jamanetworkopen.2021.11629.CrossRef

104.

Hofhuis J, van der Rijt PGA, Vlug M. Diversity climate enhances work outcomes through trust and openness in workgroup communication. SpringerPlus. 2016;5:1. https://doi.org/10.1186/s40064-016-2499-4.CrossRef

105.

Powell W, Richmond J, Mohottige D, Yen I, Joslyn A, Corbie-Smith G. Medical mistrust, racism, and delays in preventive health screening among African-American men. Behav Med. 2019;45(2):102–17. https://doi.org/10.1080/08964289.2019.1585327.CrossRefPubMed

106.

Scharf DP, Mathews KJ, Jackson P, Hofsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved. 2010;21(3):879–97. https://doi.org/10.1353/hpu.0.0323.CrossRef

107.

Chukwueke UN, Vera E, Acquaye A, et al. SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. Neuro-Oncol. 2021;23(11):1845–58. https://doi.org/10.1093/neuonc/noab172.CrossRefPubMedPubMedCentral

108.

Budhu J, Porter A, Jackson S, et al. DISP-14. Defining interventions and metrics to improve diversity in CNS clinical trial participation: a SNO and RANO effort. Neuro-Oncol. 2022;24:vii130–vii130. https://doi.org/10.1093/neuonc/noac209.496.CrossRef

109.

Nooka AK, Behera M, Lonial S, Dixon MD, Ramalingam SS, Pentz RD. Access to Children’s Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: racial/ethnic dissimilarities in participation. Cancer. 2016;122(20):3207–14. https://doi.org/10.1002/cncr.30090.CrossRefPubMed

2024 ASCO Annual Meeting

Springer Medicine

Disparities in Neuro-Oncology

Abstract

Purposeof Review

Recent Findings

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purposeof Review

Recent Findings

Please log in to get access to this content

Other articles of this Issue 12/2023

Neuromodulation for Post-Stroke Motor Recovery: a Narrative Review of Invasive of Invasive and Non‑Invasive Tools

Exploring the Role of Locus Coeruleus in Alzheimer’s Disease: a Comprehensive Update on MRI Studies and Implications

Vagus nerve stimulation in ischemic stroke

Revisiting Functional Dysconnectivity: a Review of Three Model Frameworks in Schizophrenia

Neural Control of REM Sleep and Motor Atonia: Current Perspectives

Autonomic Manifestations of Long-COVID Syndrome